• 1
    Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 52025.
  • 2
    UK Haemophilia Centre Doctors’ Organisation von Willebrand Disease Working Party. Guidelines for the diagnosis and management of von Willebrand disease. Haemophilia 1997; 3 (Suppl. 2): 48.
  • 3
    Mannucci PM, Cattaneo M. Desmopressin: a nontransfusional treatment of hemophilia and von Willebrand disease. Haemostasis 1992; 22: 27680.
  • 4
    Mazurier C, Gaucher C, Jorieux S, Goudemand M. Biological effect of desmopressin in eight patients with type 2N (‘Normandy’) von Willebrand disease. Collaborative Group. Br J Haematol 1994; 88: 84954.
  • 5
    De Sio L, Mariani G, Muzzuconi MG, Chistolini A, Tirindelli MC, Mandelli F. Comparison between subcutaneous and intravenous DDAVP in mild and moderate hemophilia A. Thromb Haemost 1985; 54: 3879.
  • 6
    Lethagen S, Harris AS, Sjorin E, Nilsson M. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility. Thromb Haemost 1987; 58: 10336.
  • 7
    Lethagen S, Ragnarson Tennvall G. Self-treatment with desmopressin intranasal spray in patients with bleeding disorders: effect on bleeding symptoms and socioeconomic factors. Ann Hematol 1993; 66: 25760.
  • 8
    Dunn AL, Powers JR, Ribeiro MJ, Rickles FR, Abshire TC. Adverse events during use of intranasal desmopressin for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia 2000; 6: 114.
  • 9
    Holmberg L, Nilsson IM, Borge L, Gunnarsson M, Sjorin E. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type IIB von Willebrand's disease. N Engl J Med 1983; 309: 81621.
  • 10
    Casonato A, Fabris F, Girolami A. Platelet aggregation and pseudothrombocytopenia induced by 1-desamino-8- D-arginine vasopressin (DDAVP) in type IIB von Willebrand's disease patient. Eur J Hematol 1990; 45: 3642.
  • 11
    Casonato A, Sartori MT, de Marco L, Girolami A. 1-Desamino-8-D-arginine vasopressin (DDAVP) infusion in type IIB von Willebrand's disease: shortening of bleeding time and induction of a variable pseudothrombocytopenia. Thromb Haemost 1990; 64: 11720.
  • 12
    Casonato A, Pontara E, Dannhaeuser D et al. Re-evaluation of the therapeutic efficacy of DDAVP in type IIB von Willebrand's disease. Blood Coag Fibrinol 1994; 5: 95964.
  • 13
    Casonato A, Steffan A, Pontara E et al. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation. Thromb Haemost 1999; 81: 2248.
  • 14
    Fowler WE, Berkowitz LR, Roberts HR. DDAVP for type IIB von Willebrand disease. Blood 1989; 74: 185960.
  • 15
    McKeown LP, Connaghan G, Wilson O, Hausmann K, Merryman P, Gralnick HR. 1-Desamino-8-arginine-vasopressin corrects the hemostatic defects in type 2B von Willebrand's disease. Am J Hematol 1996; 51: 15863.
  • 16
    Castaman G, Rodeghiero F. Desmopressin and type IIB von Willebrand disease. Haemophilia 1996; 2: 737.
  • 17
    Bond L, Bevan D. Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med 1988; 318: 121.
  • 18
    Lowe GD. Desmopressin and myocardial infarction. Lancet 1989; 1: 8956.
  • 19
    McLeod BC. Myocardial infarction in a blood donor after administration of desmopressin. Lancet 1990; 336: 11378.
  • 20
    Grunwald Z, Sather SD. Intraoperative cerebral infarction after desmopressin administration in infant with end-stage renal disease. Lancet 1995; 345: 13645.
  • 21
    Ray JG. DDAVP use during pregnancy: an analysis of its safety for mother and child. Obstet Gynecol Surg 1998; 53: 4505.
  • 22
    Smith TJ, Gill JC, Ambruso DR, Hathaway WE. Hyponatremia and seizures in young children given DDAVP. Am J Hematol 1989; 31: 199202.
  • 23
    Sutor AH. DDAVP is not a panacea for children with bleeding disorders. Br J Haematol 2000; 108: 21727.
  • 24
    Fernandez Lucas M, Liano F, Navarro JF, Sastre JL, Quereda C, Ortuno J. Acute renal failure secondary to antifibrinolytic therapy. Nephron 1995; 69: 4789.
  • 25
    British National Formulary. William Clowes, Suffolk, 2002; 44: 714.
  • 26
    Lindoff C, Rybo G, Astedt B. Treatment with tranexamic acid during pregnancy, and the risk of thromboembolic complications. Thromb Haemost 1993; 70: 23840.
  • 27
    Menache D, Aronson DL. New treatments of von Willebrand disease: plasma derived von Willebrand factor concentrates. Thromb Haemost 1997; 78: 56670.
  • 28
    Mannucci PM, Moia M, Rebulla P, Altieri D, Monteagudo J, Castillo R. Correction of the bleeding time in treated patients with severe von Willebrand disease is not solely dependent on the normal multimeric structure of plasma von Willebrand factor. Am J Hematol 1987; 25: 5565.
  • 29
    Cumming AM, Fildes S, Cumming IR, Wensley RT, Redding OM, Burn AM. Clinical and laboratory evaluation of National Health Service factor VIII concentrate (8Y) for the treatment of von Willebrand's disease. Br J Haematol 1990; 75: 2349.
  • 30
    Pasi KJ, Williams MD, Enayat MS, Hill FG. Clinical and laboratory evaluation of the treatment of von Willebrand's disease patients with heat-treated factor VIII concentrate (BPL 8Y). Br J Haematol 1990; 75: 22833.
  • 31
    Dobrkovska A, Krzensk U, Chediak JR. Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. Haemophilia 1998; 4 (Suppl. 3): 339.
  • 32
    Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 1992; 79; 31307.
  • 33
    Metzner HJ, Hermentin P, Cuesta-Linker T, Langner S, Muller HG, Friedebold J. Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis. Haemophilia 1998; 4 (Suppl. 3): 2532.
  • 34
    Makris M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemost 2002; 88: 3878.
  • 35
    Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002; 88: 3789.
  • 36
    Lusher JM. Clinical guidelines for treating von Willebrand disease patients who are not candidates for DDAVP – a survey of European physicians. Haemophilia 1998; 4 (Suppl. 3): 114.
  • 37
    Berntorp E, Nilsson IM. Use of a high-purity factor VIII concentrate (Hemate-P) in von Willebrand's disease. Vox Sang 1989; 56: 2127.
  • 38
    Scharrer I, Vigh T, Aygoren-Pursun E. Experience with Haemate-P in von Willebrand's disease in adults. Haemostasis 1994; 24: 298303.
  • 39
    Kreuz W, Mentzer D, Becker S, Scharrer I, Kornhuber B. Haemate-P in children with von Willebrand's disease. Haemostasis 1994; 24: 30410.
  • 40
    Lubetsky A, Schulman S, Varon D et al. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-PTM) in patients with von Willebrand disease. Thromb Haemost 1999; 81: 22933.
  • 41
    Mannucci PM, Chediak J, Hanna W et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002; 99: 4506.
  • 42
    Federici AB, Baudo F, Caracciolo C et al. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study. Haemophilia 2002; 8: 7617.
  • 43
    Mazurier C, de Romeuf C, Parquet-Gernez A, Jorieux S, Goudemand M. In vitro and in vivo evaluation of a factor VIII concentrate heat-treated to inactivate HTLV-III/LAV viruses. Favourable effects of heating on the von Willebrand factor. Vox Sang 1987; 52: 26571.
  • 44
    Mazurier C, De Romeuf C, Parquet-Gernez A, Goudemand M. In vitro and in vivo characterization of a high-purity, solvent/detergent-treated factor VIII concentrate: evidence for its therapeutic efficacy in von Willebrand's disease. Eur J Haematol 1989; 43: 714.
  • 45
    Goudemand J, Negrier C, Ounnoughene N, Sultan Y. Clinical management of patients with von Willebrand's disease with a VHP vWF concentrate: the French experience. Haemophilia 1998; 4 (Suppl. 3): 4852.
  • 46
    Smith MP, Rice KM, Bromidge ES et al. Continuous infusion therapy with very high purity von Willebrand factor concentrate in patients with severe von Willebrand disease. Blood Coag Fibrinol 1997; 8: 612.
  • 47
    Castillo R, Monteagudo J, Escolar G, Ordinas A, Magillon M, Martin Villar J. Hemostatic effect of normal platelet transfusion in severe von Willebrand disease patients. Blood 1991; 77: 19015.
  • 48
    Sindet-Pedersen S. Haemostasis in oral surgery–the possible pathogenetic implications of oral fibrinolysis on bleeding. Experimental and clinical studies of the haemostatic balance in the oral cavity, with particular reference to patients with acquired and congenital defects of the coagulation system. Dan Med Bull 1991; 38: 42743.
  • 49
    Kadir RA, Economides DL, Sabin CA, Pollard D, Lee CA. Assessment of menstrual blood loss and gynaecological problems in patients with inherited bleeding disorders. Haemophilia 1999; 5: 408.
  • 50
    Edlund M, Blomback M, von Schoultz B, Andersson O. On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol 1996; 53: 2348.
  • 51
    Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998; 351: 4859.
  • 52
    Lahteenmaki P, Haukkamaa M, Puolakka J et al. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. BMJ 1998; 316: 11226.
  • 53
    Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 1996; 313: 57982.
  • 54
    Foster PA. The reproductive health of women with von Willebrand Disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 74: 78490.
  • 55
    Preston JT, Cameron IT, Adams EJ, Smith SK. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol 1995; 102: 4016.
  • 56
    Ong YL, Hull DR, Mayne EE. Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid. Haemophilia 1998; 4: 635.
  • 57
    Rodeghiero F, Castaman G, Mannucci PM. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb Haemost 1996; 76: 6926.
  • 58
    Kobrinsky N, Goldsmith J. Efficacy of Stimate (desmopressin acetate) nasal spray, 1.5 mg ml−1, for the treatment of menorrhagia in women with inherited bleeding disorders. Blood 1997; 90 (Suppl. 1): 106.
  • 59
    Janssen CA, Scholten PC, Heintz AP. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol 1995; 85: 97782.
  • 60
    Giles AR, Hoogendoorn H, Benford K. Type IIB von Willebrand's disease presenting as thrombocytopenia during pregnancy. Br J Haematol 1987; 67: 34953.
  • 61
    Hill FG. Haematological disorders. Clin Obstet Gynaecol 1982; 9: 7590.
  • 62
    Fressinaud E, Meyer D. International survey of patients with von Willebrand disease and angiodysplasia. Thromb Haemost 1993; 70: 546.
  • 63
    Ramsay DM, Buist TA, Macleod DA, Heading RC. Persistent gastrointestinal bleeding due to angiodysplasia of the gut in von Willebrand's disease. Lancet 1976; 2: 2758.
  • 64
    Lavabre Bertrand T, Navarro M, Blanc P, Larrey D, Michel H, Rouanet C. Von Willebrand's disease, digestive angiodysplasia, and estrogen-progesterone treatment. Am J Hematol 1994; 46: 2545.
  • 65
    Hodgson H. Hormonal therapy for gastrointestinal angiodysplasia. Lancet 2002; 359: 16301.
  • 66
    Orsi P, Guatti-Zuliani C, Okolicsanyi L. Long-acting octreotide is effective in controlling rebleeding angiodysplasia of the gastrointestinal tract. Dig Liver Dis 2001; 33: 3304.
  • 67
    Cattaneo M, Moia M, Delle Valle P, Castellana P, Mannucci PM. DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor. Blood 1989; 74: 19725.
  • 68
    Foster PA. A perspective on the use of FVIII concentrates and cryoprecipitate prophylactically in surgery or therapeutically in severe bleeds in patients with von Willebrand disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 74: 13708.
  • 69
    Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90: 251521.
  • 70
    Gralnick HR, Williams SB, McKeown LP et al. DDAVP in type IIa von Willebrand's disease. Blood 1986; 67: 4658.
  • 71
    Ciavarella N, Schiavoni M, Valenzano E, Mangini F, Inchingolo F. Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasis 1996; 26 (Suppl. 1): 1504.
  • 72
    Federici A, Mannucci P. Diagnosis and management of von Willebrand disease. Haemophilia 1999; 5 (Suppl. 2): 2837.
  • 73
    Veyradier A, Jenkins CSP, Fressinaud E, Meyer D. Willebrand Syndrome: from pathophysiology to management. Thromb Haemost 2000; 4: 17582.
  • 74
    AHCPR. Acute Pain Management: Operative or Medical Procedures and Trauma. Washington: Agency of Health Care Policy and Research Publications. United States Department of Health and Human Services, 1992.